BHVN:NYE-Biohaven Pharmaceutical Holding Co Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 38.97

Change

0.00 (0.00)%

Market Cap

USD 3.44B

Volume

0.95M

Analyst Target

USD 83.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 567.03B
HTD John Hancock Tax Advantaged Di..

N/A

USD 2.41B
DNA Ginkgo Bioworks Holdings

N/A

USD 2.17B
RCUS Arcus Biosciences Inc

N/A

USD 1.41B
NUVB Nuvation Bio Inc

N/A

USD 0.64B
ADCT ADC Therapeutics SA

N/A

USD 0.36B
PGP PIMCO Global StocksPLUS & Inco..

N/A

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.29B
ATNM Actinium Pharmaceuticals Inc

N/A

USD 0.27B
LCTX Lineage Cell Therapeutics Inc

N/A

USD 0.20B

ETFs Containing BHVN

IBRN iShares Trust - iShares N.. 4.08 % 0.00 %

N/A

USD 3.84M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.95% 46% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.95% 46% F 15% F
Trailing 12 Months  
Capital Gain 197.94% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 197.94% 100% F 99% N/A
Trailing 5 Years  
Capital Gain -37.99% 33% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.99% 22% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain 38.21% 86% B+ 93% A
Dividend Return 38.21% 86% B+ 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 91.95% 31% F 8% B-
Risk Adjusted Return 41.55% 91% A- 65% D
Market Capitalization 3.44B 97% N/A 72% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.